Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON LICENSING PARTNER SPERO THERAPEUTICS, INC. ENTERED INTO LICENSING AGREEMENT WITH PFIZER INC. FOR SPR206 IN EX-UNITED STATES AND EX-ASIA TERRITORIES

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that Spero Therapeutics, Inc. (Nasdaq: SPRO) ("**Spero**"), a licensing partner of the Company, entered into a regional licensing agreement (the "**Pfizer Licensing Agreement**") with Pfizer Inc. (NYSE: PFE) ("**Pfizer**") for SPR206, Spero's intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant ("**MDR**") Gram-negative infections in the hospital setting.

Under the terms of the Pfizer Licensing Agreement, Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-United States and ex-Asia territories. In exchange for these rights, Spero is eligible to receive up to $80 million in development and sales milestones, and high single digit to low double-digit royalties on net sales of SPR206 in these territories. Pfizer has also made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.

Under the licensing agreement with Spero that was announced in January 2019 and amended in January 2021, the Company has exclusive rights to develop, manufacture and commercialize SPR206 in Greater China, South Korea and certain Southeast Asian countries (the "**Territory**") for the treatment of MDR Gram-negative bacterial infections. The licensing agreement was amended in January 2021 for the assignment of relevant patents for SPR206 in the Territory to the Company. The Pfizer Licensing Agreement will have no impact on the Company's rights for SPR206.

INFORMATION ABOUT SPR206

SPR206 is a potentially best-in-class, novel polymyxin derivative that was designed to reduce the kidney toxicity that is seen clinically with polymyxin B and colistin. Polymyxins are antibiotics frequently used as a last resort for challenging MDR gram-negative infections, but they are associated with significant neurotoxicity and nephrotoxicity. In a double-blind, placebo-controlled Phase 1 clinical trial in healthy volunteers conducted by Spero, SPR206 appeared well tolerated at doses likely to be within a therapeutic range for MDR Gram-negative bacterial infections. Importantly, it also showed no evidence of nephrotoxicity at the doses tested.

Cautionary statement: We cannot guarantee that we will be able to develop, or ultimately market, SPR206 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, July 5, 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.